Industry News
Brand Australia wants your success stories
The Building Brand Australia Program is designed around sourcing the best possible examples of contemporary Australian capability to show to the rest of the world. [ + ]
Phosphagenics taps Labtec for pain patch design
Phosphagenics (ASX:POH) has enlisted the aid of Germany's Labtec to help design the final version of drug delivery patch TPM/oxycodone, ahead of phase III trials. [ + ]
Alchemia cancer trial cleared to continue
The DSMB overseeing Alchemia's (ASX:ACL) phase III trial of HA-Irinotecan in metastatic colorectal cancer has recommended that recruitment continue. [ + ]
Clinuvel starts final trial of Scenesse in EPP
Clinuvel (ASX:CUV) has commenced a final six-month trial of its Scenesse drug in patients with erythropoietic protoporphyria (EPP). [ + ]
Canon’s imaging science prize open for entries
Canon’s local research and development arm CiSRA, in collaboration with Sydney’s Powerhouse Museum, is calling for Australian university students to enter the 2012 Extreme Imaging competition. [ + ]
GTG breast cancer test sales gaining pace in US
Melbourne's Genetic Technologies (ASX:GTG) has revealed that its genetic test for breast cancer risk, BREVAGen, is gaining traction in the US. [ + ]
AusBiotech marks Clinical Trials Day with call for action
Marking International Clinical Trials Day 2012 (20 May), AusBiotech calls on the Government to complete the Clinical Trials Action Group (CTAG) change program to strengthen Australian’s position as a destination for clinical trials. [ + ]
Genetic safety in numbers, platypus study finds
Platypuses on the Australian mainland and in Tasmania are fighting fit but those on small islands are at high risk of being wiped out from disease, according to a University of Sydney study. [ + ]
Tropical fruit’s role as skin cancer weapon
An exciting breakthrough on the potential anti-skin-cancer properties of the tropical fruit mangosteen has earned its researcher, Flinders University PhD candidate Jing Jing Wang, a seat in the finals of a prestigious medical prize. [ + ]
The Hall effect: demonstrate relativistic effects on your mobile phone
The relativistic Hall effect, describing objects rotating at speeds comparable with the speed of light, has now been reported. The work sheds light on aspects of fundamental physics, and you can demonstrate some aspects of this with your mobile phone. [ + ]
‘Next generation’ cancer treatment ready for clinical trials
A new class of anticancer drugs which control the growth and spread of cancers and do so with minimal side effects is being developed by researchers at the University of Sydney. [ + ]
Opinion: Low scientific literacy impedes public discussion on cancer biomarkers
Translating the discovery of a potential cancer biomarker into a genuine diagnostic is tricky business, but it’s worth persevering, says Clincal Genomics CEO, Dr Lawrence LaPointe. [ + ]
New biomarker aims at affordable bowel cancer test
Australian researchers have identified genes that can be used to detect the presence of bowel cancer, raising hopes of a new cost-effective blood test. [ + ]
Plexpress announces collaboration with Admescope
Plexpress, developer of the innovative TRAC platform for high-throughput gene expression analysis, has announced a collaboration with the contract research organisation Admescope which will now include TRAC as part of its services for investigating in vitro drug interactions and preclinical ADME-Tox responses. [ + ]
REVA Medical stent trial shows positive results
Patients enrolled in a pilot trial of REVA Medical's (ASX:RVA) ReZolve coronary stent have so far suffered no major adverse coronary events. [ + ]
